Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience-Reference-Cited by-同舟云学术

Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience

Published:2018-07-10 Issue:11 Volume:25 Page:1287-1297
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Haridy J.¹²^ORCID,Wigg A.³,Muller K.³,Ramachandran J.³,Tilley E.³,Waddell V.⁴,Gordon D.⁴⁵,Shaw D.⁶⁷,Huynh D.⁸,Stewart J.⁸⁹,Nelson R.⁷⁹,Warner M.⁷⁹,Boyd M.⁷¹⁰,Chinnaratha M. A.⁷¹¹,Harding D.¹¹,Ralton L.¹⁰,Colman A.¹²,Liew D.¹³,Iyngkaran G.²,Tse E.¹²,

Affiliation:

1. University of Melbourne; Parkville Vic. Australia

2. Department of Gastroenterology; Royal Melbourne Hospital; Melbourne Vic. Australia

3. Hepatology and Liver Transplantation Unit; Flinders Medical Centre; Adelaide SA Australia

4. Department of Microbiology and Infectious Diseases; Flinders Medical Centre; Adelaide SA Australia

5. Flinders University; Bedford Park SA Australia

6. Department of Infectious Diseases; Royal Adelaide Hospital; Adelaide SA Australia

7. Faculty of Health and Medical Sciences; University of Adelaide; Adelaide SA Australia

8. Department of Gastroenterology; The Queen Elizabeth Hospital; Adelaide SA Australia

9. Department of Infectious Diseases; The Queen Elizabeth Hospital; Adelaide SA Australia

10. Department of Infectious Diseases; Lyell-McEwin Hospital; Adelaide SA Australia

11. Department of Gastroenterology; Lyell-McEwin Hospital; Adelaide SA Australia

12. Department of Gastroenterology; Royal Adelaide Hospital; Adelaide SA Australia

13. Department of Epidemiology and Preventative Medicine; Monash University; Melbourne Vic. Australia

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jvh.12943/fullpdf

Reference41 articles.

1. Hepatitis C elimination by 2030 through treatment and prevention: think global, act in local networks;Hellard;J Epidemiol Community Health,2016

2. Therapy for hepatitis C-the costs of success;Hoofnagle;N Engl J Med,2014

3. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia;Sievert;J Gastroenterol Hepatol,2014

4. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States;Rein;Dig Liver Dis,2011

5. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review;Falade-Nwulia;Ann Intern Med,2017

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is dual testing for hepatitis C necessary? Modelling the risk of removing hepatitis C antibody testing for Australian blood donations;Vox Sanguinis;2023-05-14

2. Removing hepatitis C antibody testing for Australian blood donations: A cost‐effectiveness analysis;Vox Sanguinis;2023-05-14

3. Real-World Therapeutic Outcomes of Direct-Acting Antiviral Regimens and Formidable Challenges;Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives;2023-01

4. Risk factors for loss to follow‐up after the start of direct‐acting antiviral treatment for hepatitis C virus infection;JGH Open;2022-12-30

5. Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response;World Journal of Hepatology;2022-01-27